LRRK2 and Parkinson disease: Following the evaluation of Ser(P)-1292 LRRK2 expression in CSF-derived EVs (described in section 4.1), which supported the role of auto-phosphorylated LRRK2 as potential PD biomarker [137], Wang et al. in 2020 further characterized Ser(P)-1292 LRRK2 as pharmacodynamic marker of LRRK2 drug-inhibition in macaques [181].